Related Experiment Video
Updated: Jan 1, 2026

Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
Previsit Planning Improves Pneumococcal Vaccination Rates in Childhood-Onset SLE
Vidya Sivaraman1, Kelly A Wise2, William Cotton3
1Divisions of Rheumatology, vidya.sivaraman@nationwidechildrens.org.
Insights
Pneumococcal vaccination rates in children with lupus significantly increased after implementing a quality improvement initiative. This approach successfully addressed barriers, improving protection against preventable infections in this vulnerable group.
Area of Science:
- Pediatric Rheumatology
- Autoimmune Diseases
- Infectious Disease Prevention
Background:
- Childhood-onset systemic lupus erythematosus (c-SLE) patients require immunosuppression, increasing infection risk.
- Invasive pneumococcal infections are a significant cause of mortality in pediatric SLE.
- Low pneumococcal vaccination rates pose a preventable health risk in children with c-SLE.
Purpose of the Study:
- To improve pneumococcal vaccination rates in pediatric patients with systemic lupus erythematosus (c-SLE).
- To address barriers hindering pneumococcal vaccine uptake in this immunocompromised population.
Main Methods:
- A quality improvement project utilizing the plan-do-study-act (PDSA) methodology.
- Development of an age-based algorithm to simplify vaccination guidelines.
- Interdisciplinary team (clinical pharmacist, nurses) previsit planning for vaccine record updates and recommendations.
Main Results:
- Vaccination rates for at least one pneumococcal vaccine increased from 24.9% to 92.7% within 12 months.
- Compliance with both pneumococcal vaccines rose from 2.5% to 87.3% by 18 months, with sustained high rates.
- No serious adverse events or disease flares were observed during the intervention.
Conclusions:
- A team-based quality improvement approach effectively overcame barriers to pneumococcal vaccination in c-SLE patients.
- Significant improvements in vaccination rates were achieved without increasing provider time burden.
- Future plans include electronic health record alerts to further streamline the vaccination process.
Background:
Childhood-onset systemic lupus erythematosus (c-SLE) is a complex autoimmune disease that requires systemic immunosuppressive therapy. Infections are the second leading cause of death in these patients, with invasive pneumococcal infections being a major preventable cause of morbidity and mortality. Pneumococcal vaccination is recommended in this population; however, vaccination rates remain low.
Methods:
The plan-do-study-act method of quality improvement was applied. We calculated baseline vaccination rates for pneumococcal conjugate and pneumococcal polysaccharide vaccines in patients with c-SLE in the rheumatology clinic from January 2015 to August 2016. We developed an age-based algorithm to simplify the vaccination guidelines. The clinical pharmacist and nurses performed weekly previsit planning to update vaccine records, make targeted recommendations, and ensure vaccine availability. The primary outcome measure was the percentage patients with of c-SLE seen per month who had received age-appropriate pneumococcal vaccination.
Results:
The percentage of children receiving at least 1 pneumococcal vaccine increased from 24.9% to 92.7% by 12 months. By 18 months, the compliance rate with both pneumococcal vaccines increased from 2.5% to 87.3%, with sustained results. No serious adverse events or disease flares were reported.
Conclusions:
By identifying the major barriers to pneumococcal vaccination in our population with c-SLE, we significantly improved vaccination rates while decreasing time burden on providers. We attribute our success to a team-based quality improvement approach and plan to implement alerts in the electronic health record to streamline the process.
More Related Videos
09:20Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay
Published on: April 28, 2014
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Related Concept Videos
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia III: Complications and Assessment
Planning Nursing Care I
Preventive Healthcare Services
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: